116797 ⎘
Hydrolases acting on peptide bonds, i.e. peptidases (3.4); Metallocarboxypeptidases (3.4.17) Glutamate carboxypeptidase II (3.4.17.21)
METHOD OF TREATING PROSTATE CANCER
#2PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY
#3Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same
#4PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
#5PSMA-TARGETED NIR DYES AND THEIR USES
#6METHOD OF TREATING PROSTATE CANCER
#7METHODS FOR ADMINISTERING THERAPEUTIC DOSES OF BISPECIFIC T-CELL ENGAGING MOLECULES FOR THE TREATMENT OF CANCER
#8PSMA-TARGETED NIR DYES AND THEIR USES
#9PSMA binding ligand-linker conjugates and methods for using
#10Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
#11Site-specific conjugation of linker drugs to antibodies and resulting ADCs
#12PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
#13PSMA-targeted NIR dyes and their uses
#14PSMA-based molecular-genetic reporter system
#15Multiple proteases deficient filamentous fungal cells and methods of use thereof
#16PSMA binding ligand-linker conjugates and methods for using
#17VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY
#18Multiple proteases deficient filamentous fungal cells and methods of use thereof
#19Compositions and methods comprising KLK3 or FOLH1 antigen
#20Site-specific conjugation of linker drugs to antibodies and resulting ADCS
#21Site-specific conjugation of linker drugs to antibodies and resulting ADCS
#22Multiple protease deficient filamentous fungal cells and methods of use thereof
#23PSMA-targeted NIR dyes and their uses
#24Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
#25Prostate-associated antigens and vaccine-based immunotherapy regimens
#26PSMA binding ligand-linker conjugates and methods for using
#27PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
#28Immunogenic Fusion Proteins For The Treatment Of Cancer
#29PSMA—targeted NIR dyes and their uses
#30Prostate-specific membrane antigen binding proteins and related compositions and methods
#31PSMA-targeted NIR dyes and their uses
#32Method of detection of analyte active forms and determination of the ability of substances to bind into analyte active sites
#33PSMA-based molecular-genetic reporter system
#34Induced activation in dendritic cells
#35COMPOSITIONS AND METHODS COMPRISING KLK3 OR FOLH1 ANTIGEN
#36Site-specific conjugation of linker drugs to antibodies and resulting ADCs
#37PSMA-targeted NIR dyes and their uses
#38PSMA-targeted NIR dyes and their uses
#39Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
#40Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
#41Immunogenic fusion proteins for the treatment of cancer
#42Multiple proteases deficient filamentous fungal cells and methods of use thereof
#43PSMA binding ligand-linker conjugates and methods for using
#44VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY
#45Induced activation in dendritic cells
#46PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING FUSION PROTEIN
#47Prostate-associated antigens and vaccine-based immunotherapy regimens
#48Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
#49Prostate-associated antigens and vaccine-based immunotherapy regimens
#50PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT ALZHEIMER'S DISEASE COMPRISING GCP II MUTANT
#51Induced activation in dendritic cells
#52Compositions and methods comprising KLK3 of FOLH1 antigen
#53Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions